Suppr超能文献

肺部超声评分与胸部 X 射线评分对预测呼吸窘迫综合征新生儿应用肺表面活性剂的价值。

Lung ultrasonography score versus chest X-ray score to predict surfactant administration in newborns with respiratory distress syndrome.

机构信息

Department of Neonatology, Catholic University of the Sacred Heart, Rome, Italy.

Department of Radiology, Catholic University of the Sacred Heart, Rome, Italy.

出版信息

Pediatr Pulmonol. 2018 Sep;53(9):1231-1236. doi: 10.1002/ppul.24076. Epub 2018 Jun 5.

Abstract

OBJECTIVES

We aim to verify the diagnostic accuracy of a lung ultrasonography (LUS) score to early predict the need for surfactant therapy in newborns with respiratory distress syndrome (RDS), and to compare it with a chest X-ray score.

METHODS

In this prospective diagnostic accuracy study we included all newborns admitted for respiratory distress and initially treated with nasal CPAP. LUS was performed within 2 h from nasal CPAP positioning and in any case before surfactant administration. A chest X-ray was also performed. A LUS score and an X-ray score were used and compared. Ability of the scores to predict surfactant administration was evaluated through ROC analysis.

RESULTS

In our population of 56 newborns with mean gestational age of 31 weeks (SD 3) and mean birth weight of 1442 g (SD 520), LUS score showed higher AUC than X-ray score in early recognition of infants with respiratory distress syndrome requiring surfactant treatment (0.94; 95%CI, 0.89-0.98; P < 0.001 vs 0.80; 95%CI, 0.74-0.86; P < 0.001). It showed also higher sensitivity (86% vs 82%), higher specificity (88% vs 76%), better positive (83% vs 69%), and negative (91% vs 87%) predictive values.

CONCLUSIONS

LUS is a non-invasive, bedside and reproducible method that could improve the management of neonatal respiratory distress. It is accurate and reliable to early identify patients who will need treatment with surfactant allowing both an early treatment and a reduction of radiation exposure.

摘要

目的

我们旨在验证肺部超声(LUS)评分预测新生儿呼吸窘迫综合征(RDS)患儿需用肺表面活性物质治疗的诊断准确性,并与胸部 X 线评分进行比较。

方法

本前瞻性诊断准确性研究纳入了所有因呼吸窘迫而入院且最初接受经鼻持续气道正压通气(nCPAP)治疗的新生儿。LUS 在 nCPAP 定位后 2 小时内进行,且在任何情况下均在肺表面活性物质给药前进行。还进行了胸部 X 线检查。使用并比较了 LUS 评分和 X 线评分。通过 ROC 分析评估评分预测肺表面活性物质给药的能力。

结果

在我们的 56 例新生儿中,平均胎龄为 31 周(标准差 3),平均出生体重为 1442 克(标准差 520 克),LUS 评分在早期识别需要肺表面活性物质治疗的 RDS 患儿方面显示出高于 X 线评分的 AUC(0.94;95%CI,0.89-0.98;P<0.001 与 0.80;95%CI,0.74-0.86;P<0.001)。它还显示出更高的敏感性(86% 与 82%)、更高的特异性(88% 与 76%)、更好的阳性预测值(83% 与 69%)和阴性预测值(91% 与 87%)。

结论

LUS 是一种非侵入性、床边和可重复的方法,可以改善新生儿呼吸窘迫的管理。它可以准确可靠地早期识别需要用肺表面活性物质治疗的患者,从而实现早期治疗并减少辐射暴露。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验